Literature DB >> 3698254

Rapid suppression of complex ventricular arrhythmias with high-dose oral amiodarone.

N D Mostow, T R Vrobel, D Noon, L Rakita.   

Abstract

Although amiodarone is effective for the suppression of complex ventricular arrhythmias, a major problem with its use is the long delay between the initiation of therapy and the onset of effective suppression of arrhythmia. To test the hypothesis that rapid loading with oral amiodarone to a target serum concentration can overcome much of this delay, eight patients with refractory, sustained, hemodynamically compromising ventricular arrhythmias and 10 patients with potentially life-threatening ventricular arrhythmias were treated with a flexible, very high dose, oral loading protocol (800 to 2000 mg two to three times a day). Dosage was adjusted on the basis of amiodarone serum concentrations to maintain the trough serum concentrations between 2.0 and 3.0 micrograms/ml. Comparison of 24 hr Holter electrocardiograms obtained before and during therapy revealed statistically significant reductions in premature ventricular complexes (PVCs) and paired PVCs beginning the first day of therapy and a reduction in ventricular tachycardia (VT) beginning the second day. By day 2, four of eight patients with sustained VT and six of 10 patients with nonsustained VT showed no VT. Pulmonary arterial catheterization during the first 24 hr (mean amiodarone dose 3933 mg) revealed no significant hemodynamic alterations. Minor side effects were common (10 patients) but major side effects were rare (one patient). High-dose oral loading with amiodarone utilizing serum concentration guidelines is a safe and effective method of rapidly controlling life-threatening arrhythmias in selected patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698254     DOI: 10.1161/01.cir.73.6.1231

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Hemodynamic effects of amiodarone during acute and chronic treatment in patients with recurrent sustained ventricular tachycardia.

Authors:  M Manz; W Jung; B Lüderitz
Journal:  Clin Investig       Date:  1992-05

Review 2.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 3.  Selegiline--an overview of its role in the treatment of Parkinson's disease.

Authors:  K Wessel; I Szelenyi
Journal:  Clin Investig       Date:  1992-05

4.  Therapeutic monitoring of amiodarone and desethylamiodarone after surgical ablation of atrial fibrillation-evaluation of the relationship between clinical effect and the serum concentration.

Authors:  Erika Hrudikova; Milan Grundmann; Martin Kolek; Romana Urinovska; Ivana Kacirova
Journal:  Saudi Pharm J       Date:  2021-03-31       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.